Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 7/20 | 0.57 |
| ▸ | CNR2 | P34972 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4632916 | 0.95 | CNR1 (0.59) | GABRA2GABRB2CNR1CNR2 | |
| SCHEMBL12907765 | 0.93 | GABRA2 (0.56) | GABRA2GABRB2CNR1CNR2 | |
| SCHEMBL2874753 | 0.93 | CNR1 (0.66) | GABRA2GABRB2CNR1CNR2KCNH2 | |
| SCHEMBL12053889 | 0.92 | CNR1 (0.62) | GABRA2GABRB2CNR1CNR2KCNH2 | |
| SCHEMBL4911810 | 0.90 | GABRA2 (0.58) | GABRA2GABRB2CNR1CNR2 | |
| SCHEMBL13672836 | 0.90 | CNR1 (0.57) | GABRA2GABRB2CNR1CNR2KCNH2 | |
| SCHEMBL3997267 | 0.90 | CNR1 (0.59) | GABRA2GABRB2CNR1CNR2KCNH2 | |
| SCHEMBL30961554 | 0.89 | CNR1 (0.68) | GABRA2GABRB2CNR1CNR2 | |
| SCHEMBL2627954 | 0.89 | CNR1 (0.68) | GABRA2GABRB2CNR1CNR2 | |
| SCHEMBL2865960 | 0.87 | CNR1 (0.61) | GABRA2GABRB2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084467-B2 | For both CB1 and CB2 receptor sites; 3-(N-hetero)amido-5-phenyl pyrazoles; memory deficits associated with aging or nervous system disorders, obesity, schizophrenia, septic shock | UNIVERSITY OF CONNECTICUT (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084467-B2 | For both CB1 and CB2 receptor sites; 3-(N-hetero)amido-5-phenyl pyrazoles; memory deficits associated with aging or nervous system disorders, obesity, schizophrenia, septic shock | UNIVERSITY OF CONNECTICUT (US) | 2011-12-27 | — | — | US | disclosed |
| US-7745440-B2 | Pyrazole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745440-B2 | Pyrazole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090258902-A1 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7514068-B2 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7393842-B2 | Pyrazole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393842-B2 | Pyrazole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2008-07-01 | — | — | US | disclosed |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007033366-A2 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-02-26 | — | — | US | disclosed |
| US-6645985-B2 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them, and method of treating | SANOFI (FR) | 2003-11-11 | — | — | US | disclosed |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6432984-B1 | CANNABINOID RECEPTOR ANTAGONISTS; TREATMENT OF OBESITY, DRUG ADDICTION, ALCHOLISM, PSYCHOLOGICAL, AND EATING DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258902-A1 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CNR2, CNR1, GPR119 | GABRA2 293/4885GABRB2 180/4885CNR1 2/4885 |
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | GABRA2 81/4885GABRB2 177/4885CNR1 1/4885 |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CNR2, CNR1, GPR119 | GABRA2 293/4885GABRB2 180/4885CNR1 2/4885 |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CNR2, CNR1, GPR119 | GABRA2 550/4885GABRB2 309/4885CNR1 2/4885 |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | GABRA2 81/4885GABRB2 177/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.